If full transparency, the following press release was submitted to SOURCE media via its business wire service.
NATICK – Naveris, Inc., a Natick-based molecular diagnostics company, announced the presentation of significant new data at the plenary session of the ASTRO 2022 Multidisciplinary Head and Neck Cancers Symposium supporting the clinical value of its flagship diagnostic test, NavDx®.
In a real-world analysis of 1,076 patients treated for HPV-driven head and neck cancer in the surveillance setting across 124 U.S. medical sites, the NavDxblood test accurately identified 80 patients with recurrent cancers, showing an overall positive predictive value of 95%.
A positive NavDx test, which measures tumor tissue modified viral HPV DNA (“TTMV-HPV DNA”), was the first indication of recurrence in 72% of these patients, previously considered to be disease-free, in which imaging and/or biopsy subsequent to the positive NavDxtest confirmed the presence of recurrence.
“NavDx has fundamentally transformed, for the better, how patients treated for HPV-driven cancers are surveilled for the development of recurrence,” said Naveris CEO Piyush Gupta, PhD. “This real-world study, the largest of its kind for HPV-related cancers, clearly shows how integration of Naveris’ innovative technology empowers physicians with actionable data in their management of patients.”
“These data add to a growing and impactful literature on the power of circulating TTMV-HPV DNA to easily and accurately detect persistent or recurrent disease among patients with HPV-driven head and neck cancers,” said Glenn Hanna, MD, a first author of the study and medical oncologist at the Dana-Farber Cancer Institute. “These data will no doubt inform future guidelines and may reshape surveillance practices. In addition, I expect we will be integrating TTMV-HPV DNA testing as a biomarker to guide treatment decisions for our patients.”
The Multidisciplinary Head and Neck Cancers Symposium provides the most up-to-date information on multidisciplinary therapies, clinical research, treatment strategies, supportive care, scientific breakthroughs, and toxicity mitigation for the entire head and neck cancer community.
Naveris’ mission is to improve outcomes for the millions of individuals at risk of developing viral cancers. The company applies its innovative and patented technology to develop molecular diagnostics which enable earlier detection of viral cancers. Naveris’ first commercial-stage diagnostic, NavDx®, is a blood test that supports the clinical management of patients with HPV-driven cancers. Since its launch in 2020, NavDx has become integrated into daily medical practice by over 500 physicians at 200 medical sites, including the majority of the leading Oncology Centers of Excellence in the U.S.